• 한국자원식물학회:학술대회논문집
• /
• 한국자원식물학회 2000년도 제7차 국제 심포지움(생약자원개발에 관한연구) 및 추계정기 학술발표회 초록집
• /
• pp.1-1
• /
• 2000

• 한국환경성돌연변이발암원학회:학술대회논문집
• /
• 한국환경성돌연변이발암원학회 2004년도 춘계학술대회
• /
• pp.74-75
• /
• 2004

• Journal of Pharmaceutical Investigation
• /
• 제10권3호
• /
• pp.51-77
• /
• 1980

A comparison of worldwide drug registration requirements on scientific data required by the different regulatory authorities for the investigational new drug and new drug application for human uses was briefly reviewed and as one of administrative processings on review and evaluation of applications, the functions of scientific advisory committees were reviewed.

• 한국해양바이오학회지
• /
• 제2권4호
• /
• pp.201-208
• /
• 2007

Polychlorinated biphenyls (PCBs) are anthropogenic contaminants found globally in water, ice, soil, air and sediment. Modern analytical techniques allow us to determine these chemicals in environmental matrices at parts per trillion levels or lower. Environmental forensic on PCBs opens up new avenues of investigation such as transport and fate of water masses in oceans, sedimentation, onset of primary production, migration of marine mammals, their population distribution and pharmacokinetics of drugs inside organisms. By virtue of persistence, bioaccumulation, bioconcentration and structure-activity relationship PCBs emerge as unconventional chemical tracers of new sort.

• Journal of Interdisciplinary Genomics
• /
• 제3권2호
• /
• pp.25-29
• /
• 2021

Myotonic muscular dystrophy is a disease characterized by progressive muscle weakness with myotonia and multiorgan involvement. Two subtypes have been recognized; each subtype is caused by nucleotide repeat expansion. So far, there has been no cure for myotonic muscular dystrophy. In this article, we introduce ongoing clinical trials for new drugs to modify disease course by correcting genetic derangement or its downstream in myotonic dystrophy type 1.

• Annals of Clinical Neurophysiology
• /
• 제23권1호
• /
• pp.29-34
• /
• 2021

New therapeutics in neurology are expanding at an unprecedented pace. In addition to the classic enzyme-replacement therapies, monoclonal antibodies are increasingly being used to modulate autoimmunity. RNA therapeutics are an emerging class, together with gene and cell therapies. The nomenclature of international nonproprietary names helps us to recognize these new drugs according to their class and function. Suffixes denote major categories of the drug, while infixes provide additional information such as the source and target.

• 제어로봇시스템학회:학술대회논문집
• /
• 제어로봇시스템학회 2004년도 ICCAS
• /
• pp.326-329
• /
• 2004

In this paper, we show a new form of blood pressure controller combined PI control with $H_{\infty}$ loop-shaping. Hypertensive patients or post-operative patients need to maintain normally blood pressure. Exact regulation of blood pressure is needed for maintaining variable blood pressure of preventing complications. The regulation of blood pressure is achieved by injecting drugs, and usually sodium nitroprusside is used as those kinds of drugs. It is necessary to control the infusion rate sodium-nitroprusside carefully to achieve the desired blood pressure. It has been known that regulation of blood pressure by automatic controller is more effective than regulation of blood pressure by human operators. The control of blood pressure has many constraints and uncertainties. Most of biological system has the time-varying variables and the side effects such as increased risk of sepsis and organ failure. To solve such a problem, we design a new robust PI controller using $H_{\infty}$ loop-shaping to decrease noise effects that come out from human body and errors for time delay. The system with designed controller shows more stable control of mean blood pressure and more robust performance for uncertainties. Validation methods for the control performance are confirmed to computer simulations.

• BMB Reports
• /
• 제43권4호
• /
• pp.245-249
• /
• 2010

GDH has been known to be related with hyperinsulinism-hyperammonemia syndrome. We have screened new drugs with a view to developing effective drugs modulating GDH activity. In the present work, we investigated the effects of a new drug, KHG26377 on glutamate formation and GDH activity in cultured rat islets. When KHG26377 was added to the culture medium for 24 h prior to kinetic analysis, the $V_{max}$ of GDH was decreased by 59% whereas $K_m$ is not significantly changed. The concentration of glutamate decreased by 50% and perfusion of islets with KHG26377 reduced insulin release by up to 55%. Our results show that KHG26377 regulates insulin release by inhibiting GDH activity in primary cultured islets and support the previous studies for the connection between GDH activity and insulin release. Further studies are required to determine in vivo effects and pharmacokinetics of the drug.

• Biomolecules & Therapeutics
• /
• 제17권3호
• /
• pp.219-240
• /
• 2009

Since NF-${\kappa}B$ has been identified as a transcription factor associated with immune cell activation, groups of researchers have dedicated to reveal detailed mechanisms of nuclear factor of ${\kappa}B$ (NF-${\kappa}B$) in inflammatory signaling for decades. The various molecular components of NF-${\kappa}B$ transcription factor pathway have been being evaluated as important therapeutic targets due to their roles in diverse human diseases including inflammation, cystic fibrosis, sepsis, rheumatoid arthritis, cancer, atherosclerosis, ischemic injury, myocardial infarction, osteoporosis, transplantation rejection, and neurodegeneration. With regards to new drugs directly or indirectly modulating the NF-${\kappa}B$ pathway, FDA recently approved a proteasome inhibitor bortezomib for the treatment of multiple myeloma. Many pharmaceutical companies have been trying to develop new drugs to inhibit various kinases in the NF-${\kappa}B$ signaling pathway for many therapeutic applications. However, a gene knock-out study for $IKK{\beta}$ in the NF-${\kappa}B$ pathway has given rise to controversies associated with efficacy as therapeutics. Mice lacking hepatocyte $IKK{\beta}$ accelerated cancer instead of preventing progress of cancer. However, it is clear that pharmacological inhibition of $IKK{\beta}$ appears to be beneficial to reduce HCC. This article will update issues of the NF-${\kappa}B$ pathway and inhibitors regulating this pathway.

• Bulletin of the Korean Chemical Society
• /
• 제35권12호
• /
• pp.3627-3631
• /
• 2014

In this study we examined two ester-containing cross-links, hex-2-enyl acetate and hex-2-enyl propionate, as new cross-linking systems for helix stabilization of short peptides. We demonstrated that these hexenyl ester cross-links can be readily installed via a ruthenium-mediated ring-closing metathesis reaction of L-aspartic acid 4-allyl ester or L-glutamic acid 5-allyl ester at position i and (S)-2-(4'-pentenyl)alanine at position i+4 using second generation Hoveyda-Grubbs catalyst at $60^{\circ}C$. Between these two cross-links, we found that the hex-2-enyl propionate significantly stabilizes the ${\alpha}$-helical conformations of short model peptides. The helix-stabilizing effects of the hex-2-enyl propionate tether appear to be as powerful as Verdine's i,i+4 all-hydrocarbon stapling system, which is one of the most widely used and the most potent helix-stabilizing cross-linking systems. Furthermore, the hex-2-enyl propionate bridge is reasonably robust against non-enzymatic hydrolytic cleavage at a physiological pH. While extended studies for probing its chemical scopes and biological applications are needed, we believe that this new helix-stabilizing system could serve as a useful chemical tool for understanding protein folding and designing conformationally-constrained peptide drugs.